| Document |
Document Title |
|
WO/1996/026201A1 |
Certain benzopyran antiestrogens are disclosed for treating estrogen sensitive diseases such as breast cancer. Prodrug forms provide ease of manufacturing, good shelf life, and bioavailibility, and preferred stereoisomers are shown to be...
|
|
WO/1996/025935A1 |
A method of treating adenosine depletion in a subject in need of such treatment is disclosed. The method comprises administering to the subject folinic acid or a pharmaceutically acceptable salt thereof in an amount effective to treat ad...
|
|
WO/1996/023503A1 |
Competitive progesterone antagonists (antigestagenes) are useful to prepare medicaments for treating dysfunctional uterine bleeding (metrorrhagia, menorrhagia, hypermenorrhea).
|
|
WO/1996/019212A1 |
The invention concerns the use of pure boswellic acid, a physiologically acceptable salt, a derivative, a salt of this derivative or a plant preparation containing boswellic acid to produce a medicament for the treatment of brain tumours.
|
|
WO/1996/019196A1 |
The invention relates to an intravaginal drug delivery device for administration to a female mammal of certain 17'beta'-oestradiol precursors at a substantially constant rate for a period of at least three weeks. The 17'beta'-oestradiol ...
|
|
WO/1996/013268A2 |
This invention is directed to a method of attenuating or preventing the adverse side-effects of a perfluorochemical (PFC) emulsion on the hemostatic system and serum chemistry of an animal. The method includes intravenously administering...
|
|
WO/1996/013474A1 |
The method described calls for primary and secondary alcohols to be reacted with perfluorobutane sulphonyl fluoride, or with higher homologues such as perfluorooctane sulphonyl fluoride, in the presence of 2-3 equivalents of strong organ...
|
|
WO/1996/010032A1 |
The invention relates to estrene steroid, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. The figure...
|
|
WO/1996/010031A1 |
The invention relates to novel, androstane steroids which are the ligand semiochemicals which bind to neuroepithelial receptors.
|
|
WO/1996/005216A1 |
The invention concerns novel estra-1,3,5(10)-triene amidosulphamates with an R-SO2-O- group in the 3-position, R being an R1R2N- group in which R1 and R2, independently of each other, are a hydrogen atom, an alkyl group with 1 to 5 C-ato...
|
|
WO/1996/004917A1 |
A remedy for myotonic dystrophy, containing dehydroepiandrosterone sulfate or a pharmacologically acceptable salt thereof, being efficacious for myotonia, adynamia and amyotrophy, and having a high safety.
|
|
WO/1996/004912A1 |
The use of ketoconazole or molecules resembling ketoconazole but with some side-chains, not affecting the biological activity compared to ketoconazole, changed, for the manufacture of drugs for medical treatment of diabetes mellitus type...
|
|
WO/1996/003419A1 |
Dammara compounds have immunosuppressant and anti-inflammatory activity and are useful as pharmaceuticals, particularly for use as immunosuppressant and anti-inflammatory agents. 17'alpha' dammara compounds are novel and are included per...
|
|
WO/1995/030684A1 |
17'beta'-Cyano-3,17'alpha'-dihydroxy-6-methylandrosta-3,5,9(
11)-triene 3-ethyl ether (II) is prepared by reacting 3-hydroxy-6-methylandrosta-3,5,9(11)-trien-17-one 3- ethyl ether (I) with hydrogen cyanide at a pH of about 7 to about 11....
|
|
WO/1995/028413A1 |
Invented are 17'beta'-substituted 3-carboxy steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-'alpha'-reductase.
|
|
WO/1995/027702A1 |
Novel acridinium esters that are useful, either alone or when incorporated into liposomes, as chemiluminescent agents in binding assays (e.g., immunoassays and gene probe assays) with improved sensitivity are disclosed. In addition, the ...
|
|
WO/1995/027701A1 |
Metal-containing steroid mimic complexes are provided. Compositions containing a metal ion incorporated into a steroid skeleton structure and ligands useful in the preparation of such compositions are also provided. The metal ion is pref...
|
|
WO/1995/027724A1 |
This invention relates to 'DELTA'9(11)-dehydro-8-isoestrone, of formula (VI), to the process for its preparation, to pharmaceutical compositions containing said 'DELTA'9(11)-dehydro-8-isoestrone (VI) and to the use of said 'DELTA'9(11)-d...
|
|
WO/1995/026731A1 |
Invented is a method of treating cardiovascular disease by employing a steroid 5-'alpha'-reductase inhibiting compound.
|
|
WO/1995/026730A1 |
A combined pharmaceutical preparation has two hormonal components for sequential oral administration separately conditioned in a packaging unit that consist of a number of daily dosing units separately conditioned in and individually rem...
|
|
WO/1995/026200A1 |
A method to increase the efficiency of transduction of hematopoietic and other cells by retroviruses includes infecting the cells in the presence of fibronectin or fibronectin fragments. As can be seen in the figure, the fibronectin and ...
|
|
WO/1995/020567A1 |
A codrug composition of at least two drug compounds covalently linked to one another via a labile bond to form a single codrug composition, and methods of use of the codrug for the treatment of various medical conditions. The codrug may ...
|
|
WO/1995/019186A2 |
Metabolically labile esters, and contrast media for X-ray and magnetic resonance imaging comprising these esters, wherein the esters have formula (I) in which R3 is a steroid residue, the esters containing at least one iodine atom and/or...
|
|
WO/1995/018621A1 |
Methods for treating angiogenesis, tumors, and ocular hypertension with steroids are disclosed herein. The steroids have angiostatic activity with reduced glucocorticoid activity. A preferred steroid is 6'alpha',9'alpha'-fluoro-11'beta',...
|
|
WO/1995/018821A2 |
Novel antiandrogenic agents are provided. An exemplary group of compounds has the structural formula (I), wherein R1 through R10, a and b are as defined herein. Pharmaceutical compositions and methods for using the compounds of formula (...
|
|
WO/1995/018082A1 |
An ozonide reducing agent to be used in the ozonolysis of organic compounds, which has a wide application area and is industrially safe, inexpensive, and easy to aftertreat. The agent is a compound bearing a sulfur atom and, bonded there...
|
|
WO/1995/015166A1 |
This invention discloses a method of using an aldosterone antagonist such as spironolactone and epoxymexrenone, at a dosage which does not disrupt a patient's normal electrolyte and water-retention balance, to inhibit myocardial fibrosis...
|
|
WO/1995/014791A1 |
It has been discovered that the degree of hormonal activity of candidate ligands correlates better with degree of fit into DNA than with the strength of receptor binding, and that the receptors in the steroid/thyroid hormone/vitamin A an...
|
|
WO/1995/013287A1 |
Steroids are disclosed with radical-attracting aromatic substituents of general formulae (I) and (II). The new steroids with radical-attracting aromatic substituents are suitable active ingredients in pharmaceuticals for use in the preve...
|
|
WO/1995/013076A1 |
The present invention pertains to new pharmaceutical preparations for prophylaxis and therapy of radical-mediated cell damage, consisting of steroids with phenolic A-ring structure-except the esterogens estradiol, estrone, estrione and t...
|
|
WO/1995/012402A1 |
The use of an estrogen compound is described for protecting a population of nerve cells from death. The compound can be used in the treatment of a subject affected by a neurodegenerative disorder, in order to prevent the loss of neuronal...
|
|
WO/1995/010284A1 |
The instant invention involves a method of treating and/or reversing androgenic alopecia and promoting hair growth, and methods of treating acne vulgaris, seborrhea, and female hirsutism, by administering to a patient in need of such tre...
|
|
WO/1995/010527A1 |
Novel di- and tri-methyl androst-5-ene-3,17-diols, having from 1 to 2 methyl substituents and optionally an hydroxyl group at the 7 position are provided. The compounds may be used prophylactically and therapeutically for activities asso...
|
|
WO/1995/007081A1 |
The invention relates to a preparation for substitution therapy and oral contraception comprising at least one progestogen and at least one estrogen in which the estrogen dose varies with a periodicity such that blood loss is substantial...
|
|
WO/1995/006474A1 |
Nucleosides and linked nucleosides functionalized to include alkylthiol chemical functionality at ribofuranosyl positions, nucleosidic base positions, or on internucleoside linkages. In certain embodiments, the compounds of the invention...
|
|
WO/1995/006472A1 |
A method for promoting weight control by treating a subject with a therapeutic amount of one of the 'DELTA'5-androstenes listed below to stimulate weight control without affecting appetite or inducing the synthesis of sex hormones. 'DELT...
|
|
WO/1995/005827A1 |
An agent is disclosed for transdermal application characterized by the fact that it contains gestoden esters with 1 to 20 carbon atoms in the ester group, where appropriate in combination with one or two estrogens.
|
|
WO/1995/004535A1 |
The application discloses methods of making medicaments for treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural ...
|
|
WO/1995/004283A1 |
The present invention discloses novel immunogens, antibodies prepared from such immunogens, and labeled reagents useful in immunoassays for the detection and quantification of testosterone in a test sample. Also disclosed are immunoassay...
|
|
WO/1995/004070A1 |
New 15,15-dialkyl-substituted derivatives of the estradiol of general formula (I), in which R1 and R2, independently of one another, are each a hydrogen atom or a straight-chain alkanoyl group with 1 to 10 carbon atoms, a branched-chain ...
|
|
WO/1995/002607A1 |
Compounds of formula (I) wherein R1 is hydrogen or methyl; R2 is methyl; R3 is hydrogen, Alk-R4, X-Alk, C1-6-X-Alk, XCO-Alk, CN, CO-Alk, CO-Ar, CO-O-Alk, CO-NH-Alk, CO-NH-Ar, CO-NH-Het and CO-N(Alk)2; Alk is C1-12 straight or branched al...
|
|
WO/1995/001366A1 |
The present invention relates to compounds of formula (I) wherein A is a >C=O, >CHvvvOH or >CHvvvOR4 group, in which R4 is an acyl group; one or two of R1, R2 and R3 is fluorine and the others are hydrogens; provided that when R2 is fluo...
|
|
WO/1994/028904A1 |
The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e.g. an Androstane steroid, or a pharmaceutical composition containing a semiochemica...
|
|
WO/1994/028903A1 |
The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e.g. an Estrene steroid, or a pharmaceutical composition containing an Estrene steroi...
|
|
WO/1994/027609A1 |
Composition for use in androgenotherapy and having a favorable effect on the prostate hyperplasia. The composition is characterized in that it contains dihydrotestosterone in an administered quantity corresponding to a level of dihydrote...
|
|
WO/1994/026767A1 |
Androgen nucleus derivatives having specified substituents at the 17alpha position are disclosed for use as antiandrogens for the treatment of androgen-dependent diseases. In some preferred embodiments, the compound EM-250 is formulated ...
|
|
WO/1994/024146A1 |
Androgens and their derivates and analogs, such as anabolic agents, are characterized by at least one substituent or substituent grouping with radical trapping properties. These compounds are used as androgen or anabolic agent substitute...
|
|
WO/1994/022878A1 |
An alkylating agent contains an aluminium reagent Alk3-mAlLm, in which Alk stands for a methyl, ethyl, n- or i-propyl, n-, i- or tert.-butyl, pentyl, hexyl, heptyl or octyl group, which may all also be branched, L stands for an ethoxy gr...
|
|
WO/1994/022491A1 |
New technetium and rhenium chelate compounds are disclosed, as well as a process for preparing the same, radiopharmaceuticals containing these compounds, conjugates of these compounds with substances which selectively accumulate in disea...
|
|
WO/1994/022492A1 |
New bifunctional chalcogen-atom interrupted chelators, pharmaceutical containing these compounds, their use in radiodiagnosis and radiotherapy as well as a process for producing these compounds are disclosed. In the compound having gener...
|
